LUNAPHORE-TECHNOLOGIES
Lunaphore , a Swiss life sciences company developing technologies to enable spatial biology in every laboratory, today announced that it has deployed its COMET™ PA instrument at Propath UK , one of Europe’s leading contract research organizations (CRO). Propath UK, a specialist in spatial proteomics and transcriptomics, is the first CRO in Europe to offer COMET™ services to researchers and the first organization to join Lunaphore’s Partner Labs Network, a network of CROs and academic core facilities that offer Lunaphore spatial biology solutions as a service to biopharmaceutical and academic researchers.
COMET™ is a strategic investment for Propath UK to expand its spatial biology service offerings with hyperplex staining and imaging, providing its biopharmaceutical research clients with unprecedented insights from tissue samples to answer biological questions. Lunaphore and Propath UK will work closely to provide a flexible service that meets the needs of researchers across various disciplines.
“We are delighted to form this partnership with Lunaphore and be able to offer our biopharmaceutical clients this highly innovative technology for spatial analysis,” said Dr. Krish Soni, Chief Executive of Propath UK. “We look forward to working closely with Lunaphore to help our clients unlock the incredible potential of hyperplex immunofluorescence through our world-class facility dedicated to spatial biology.”
“My team’s previous experience using COMET™ in a variety of applications at the University of Birmingham allowed us to validate the COMET™’s ability to produce staining results of exceptional quality and reproducibility and provided us the confidence to select Lunaphore as Propath’s hyperplex solution partner,” added Kelly Hunter, Chief Scientific Officer at Propath UK.
COMET™ is a fully automated sequential immunofluorescence (seqIF™) instrument, able to perform hyperplex staining and imaging, producing high-quality data in a robust and reproducible manner. With superior tissue profiling capabilities, the system allows multiplex analysis of up to 40 different spatial markers per tissue slide without human intervention. COMET™ has a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology in areas such as immuno-oncology, neuroscience, and infectious diseases.
“We are excited to partner with Propath UK to expand their spatial biology capabilities,” said Ata Tuna Ciftlik, Chief Executive Officer at Lunaphore. “Propath UK is a highly specialized CRO with spatial biology capabilities who can bring spatial biology solutions to BioPharma. We quickly realized that combining the know-how of the Propath UK team and the versatility of COMET™, with its flexible and streamlined panel development capability using validated antibodies, we will be able to bring outstanding results to the end customers.”
To learn more about the COMET™ PA platform, please visit: https://lunaphore.com/products/comet/
To learn more about Lunaphore, please visit: https://lunaphore.com/
To learn more about Propath UK, please visit: https://propath.co.uk
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore has developed a game-changing chip technology which can extract spatial proteomic and genomic data from tumors and transform any simple assay into multiplex spatial biology without complexity. Lunaphore empowers researchers to push the boundaries of research to ultimately develop the next generation personalized therapies. For further information on Lunaphore and its products, please visit www.lunaphore.com .
About Propath UK
Propath UK is a specialist CRO providing research services in molecular pathology, spatial biology and histopathology for the global biopharmaceutical sector. The company offers a range of technologies for spatial proteomic and transcriptomic tissue analysis, including now the Lunaphore COMET™ platform for hyperplex IHC analysis. Propath’s reputation has been gained over the past 40 years by providing a consistent and responsive service across thousands of pre-clinical and clinical studies. To learn more, please visit www.propath.co.uk .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503005687/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Murata Automotive-Compliant Chip Ferrite Beads Deliver Wide Band Noise Suppression of High-Frequency (5.9GHz) C-V2X19.6.2025 04:00:00 CEST | Press release
The new BLM15VM series is ideal for automotive powertrains and safety applications. It supports high frequencies. 1000Ω (Typ.) @5.9GHz. With its compact 0402-inch size (1.0×0.5mm) can operate at temperatures ranging from -55 to 150°C. And it is compliant with AEC-Q200. Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) continues to push the envelope in automotive noise suppression technology with another industry first. By leveraging proprietary material technology and optimized structural design, the company’s new BLM15VM series of automotive-compliant chip ferrite beads deliver wide-band noise suppression of high-frequency (5.9GHz) 5G vehicle-to-everything (5G-V2X) applications that exhibit high impedance. Mass production is scheduled to begin in July 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618511573/en/ [Murata Manufacturing Co., Ltd.] New Chip Ferrite Beads for Automotive In recent years, t
AV and UAS Denmark Establish Strategic Partnership to Advance Allied UAS Capabilities in Europe18.6.2025 22:30:00 CEST | Press release
AeroVironment, Inc. (“AV”) (NASDAQ: AVAV) today announced it has signed a Memorandum of Understanding (MOU) with Hans Christian Andersen Aiport in Odense, Denmark–home to the UAS Denmark Test Center–to explore joint utilization of the center’s expansive airspace and advanced test facilities. The agreement aims to leverage UAS Denmark’s strategic range and infrastructure to support AV’s uncrewed aircraft system (UAS) demonstration operations, mission training, and customer integration activities across the region. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250618380337/en/ JUMP 20 executes a seamless landing on a moving ship (Photo: AV) The collaboration is expected to enable joint research and development (R&D) initiatives and accelerate the growth of the UAS Denmark Test Center as a regional epicenter for advanced UAS innovation, evaluation, and operational readiness. "This MOU represents a significant milestone in expa
Stone Harbor Investment Partners Introduces Emerging Markets Climate Impact Debt Fund18.6.2025 22:05:00 CEST | Press release
Actively managed, sustainable UCITS fund targets emerging market countriesThis is a marketing communication. Stone Harbor Investment Partners, an investment manager of Virtus Investment Partners, Inc. (NYSE: VRTS), has launched the Stone Harbor Emerging Markets Climate Impact Debt (Bloomberg: STHEMDI) (the “Fund”), a UCITS fund classified as Article 9 under the Sustainable Finance Disclosure Regulation (SFDR) that addresses decarbonization efforts occurring in Emerging Markets (EM) while seeking to deliver attractive long-term total returns for investors. The Fund invests in sustainable debt issued with proceeds dedicated to environmental activities, assets, projects or expenditures, with social bonds also permissible, of EM corporate, sovereign, quasi-sovereign and supranational issuers in hard currency. The Fund, with a sustainable objective to promote the transition towards an environmentally and socially sustainable economy, seeks to outperform the J.P Morgan EM Credit Green, Socia
Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma18.6.2025 21:39:00 CEST | Press release
- Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide is the first FDA-approved CD19- and CD20-targeted immunotherapy combination for adult patients with follicular lymphoma (FL) - Patients with relapsed or refractory FL achieved significantly improved progression-free survival with Monjuvi in combination with rituximab and lenalidomide in the Phase 3 registration trial - This milestone represents the second approved indication for Monjuvi in the United States Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250615896694/en/ MONJUVI logo "Patients living with relapsed or refr
Andersen Consulting fortsætter sin globale udvidelse med tilføjelsen af Azurian Consulting18.6.2025 19:49:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine evner inden for virksomhedstransformation, teknologi og kunstig intelligens via en samarbejdsaftale med Azurian Consulting. Azurian Consulting, der blev grundlagt i 2012, tilbyder en omfattende række af tjenester, herunder transformation af digital strategi, databaseret strategi, optimering af forretningsprocesser og forandringsledelse. Med base i Latinamerika hjælper Azurian Consulting kunder inden for en bred vifte af brancher såsom finansverdenen, detailhandel, forbrugervarer og fremstillingsindustrien. "Samarbejdet med Andersen Consulting åbner døren til nye markeder, styrker vores evne til at hjælpe multinationale kunder og giver vores team adgang til globale ressourcer," udtaler Nicolás Dueñas, der er administrerende direktør for Azurian Consulting. "Det repræsenterer en stærk synergi, der giver os mulighed for at kombinere vores regionale indsigt med Andersen Consultings globale platform og dermed styrke vores evne til at levere integrerede og sa
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom